Four-component Staphylococcus aureus vaccine 4C-staph enhances fcγ receptor expression in neutrophils and monocytes and mitigates S. aureus infection in neutropenic mice

Infection and Immunity

Volumn 83, Issue 8, 2015, Pages 3157-3163

  Torre, Antonina ^a   Bacconi, Marta ^a   Sammicheli, Chiara ^a   Galletti, Bruno ^a   Laera, Donatello ^a   Fontana, Maria Rita ^a   Grandi, Guido ^a,b   De Gregorio, Ennio ^a   Bagnoli, Fabio ^a   Nuti, Sandra ^a   Bertholet, Sylvie ^a   Bensi, Giuliano ^a  

^a GSK   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; STAPHYLOCOCCUS VACCINE; BACTERIUM ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG FORMULATION; FEMALE; IMMUNIZATION; IMMUNOCOMPETENT CELL; MONOCYTE; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNIZATION; MICE; MICE, INBRED C57BL; MONOCYTES; NEUTROPENIA; NEUTROPHILS; RECEPTORS, IGG; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS;

EID: 84937798472     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00258-15     Document Type: Article

References (37)

1. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339:520-532. http://dx.doi.org/10.1056/NEJM199808203390806.
2. Moellering RC. 2010. The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother 65:iv3-iv8. http://dx.doi.org/10.1093/jac/dkq250.
3. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Communityassociated methicillin-resistant Staphylococcus aureus. Lancet 375:1557-1568. http://dx.doi.org/10.1016/S0140-6736(09)61999-1.
4. Brown AF, Leech JM, Rogers TR, McLoughlin RM. 2014. Staphylococcus aureus colonization: modulation of host immune response and impact on human vaccine design. Front Immunol 4:507. http://dx.doi.org/10.3389/fimmu.2013.00507.
5. Miller LS, Cho JS. 2011. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 11:505-518. http://dx.doi.org/10.1038/nri3010.
6. Bagnoli F, Fontana MR, Soldaini E, Mishra R, Fiaschi L, Cartocci E, Nardi-Dei V, Ruggiero P, Nosari S, De Falco MG, Lofano G, Marchi S, Galletti B, Mariotti P, Bacconi M, Torre A, Maccari S, Scarselli M, Rinaudo D, Inoshima N, Savino S, Mori E, Rossi-Paccani S, Baudner B, Pallaoro M, Swennen E, Liberatori S, Norais N, MMonaci E, Wardenburg JB, Schneewind O, Bensi G, Bertholet S, Rappuoli R, Grandi G. 2015. A vaccine composition formulated with a novel TLR-7 immunopotentiator induces high and broad protection against Staphylococcus aureus. Proc Natl Acad Sci U S A 112:3680-3685. http://dx.doi.org/10.1073/pnas .1424924112.
7. Colville-Nash P, Lawrence T. 2003. Air-pouch models of inflammation and modifications for the study of granuloma-mediated cartilage degradation. Methods Mol Biol 225:181-189.
8. Delano DL, Montesinos MC, Desai A, Wilder T, Fernandez P, D'Eustachio P, Wiltshire T, Cronstein BN. 2005. Genetically based resistance to the anti-inflammatory effects of methotrexate in the airpouch model of acute inflammation. Arthritis Rheum 52:2567-2575. http://dx.doi.org/10.1002/art.21208.
9. Nickerson-Nutter CL, Medvedeff ED. 1996. The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum 39:515-521. http://dx.doi.org/10.1002/art.1780390320.
10. Rothfork JM, Dessus-Babus S, Van Wamel WJB, Cheung AL, Gresham HD. 2003. Fibrinogen depletion attenuates Staphylococcus aureus infection by preventing density-dependent virulence gene upregulation. J Immunol 171:5389-5395. http://dx.doi.org/10.4049/jimmunol.171.10.5389.
11. Bensi G, Mora M, Tuscano G, Biagini M, Chiarot E, Bombaci M, Capo S, Falugi F, Manetti AGO, Donato P, Swennen E, Gallotta M, Garibaldi M, Pinto V, Chiappini N, Musser JM, Janulczyk R, Mariani M, Scarselli M, Telford JL, Grifantini R, Norais N, Margarit I, Grandi G. 2012. Multi-high-throughput approach for highly selective identification of vaccine candidates: the group A Streptococcus case. Mol Cell Proteomics 11:M111.015693. http://dx.doi.org/10.1074/mcp.M111.015693.
12. Chiappini N, Seubert A, Telford JL, Grandi G, Serruto D, Margarit I, Janulczyk R. 2012. Streptococcus pyogenes SpyCEP influences hostpathogen interactions during infection in a murine air pouch model. PLoS One 7:e40411. http://dx.doi.org/10.1371/journal.pone.0040411.
13. Chiarot E, Faralla C, Chiappini N, Tuscano G, Falugi F, Gambellini G, Taddei A, Capo S, Cartocci E, Veggi D, Corrado A, Mangiavacchi S, Tavarini S, Scarselli M, Janulczyk R, Grandi G, Margarit I, Bensi G. 2013. Targeted amino acid substitutions impair streptolysin O toxicity and group A Streptococcus virulence. mBio 4(1):e00387-12. http://dx.doi .org/10.1128/mBio.00387-12.
14. Botelho-Nevers E, Verhoeven P, Paul S, Grattard F, Pozzetto B, Berthelot P, Lucht F. 2013. Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage. Expert Rev Vaccines 12:1249-1259. http://dx.doi.org/10.1586/14760584.2013.840091.
15. Scully IL, Liberator PA, Jansen KU, Anderson AS. 2014. Covering all the basis: preclinical development of an effective Staphylococcus aureus vaccine. Front Immunol 5:109. http://dx.doi.org/10.3389/fimmu.2014.00109.
16. Foster TJ. 2005. Immune evasion by staphylococci. Nat Rev Microbiol 3:948-958. http://dx.doi.org/10.1038/nrmicro1289.
17. Foster TJ, Geoghegan JA, Ganesh VK, Hook M. 2014. Adhesion, invasion, and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol 12:49-62. http://dx.doi.org/10.1038/nrmicro3161.
18. Kim HK, Thammavongsa V, Schneewind O, Missiakas D. 2012. Recurrent infections and immune evasion strategies of Staphylococcus aureus. Curr Opin Microbiol 15:92-99. http://dx.doi.org/10.1016/j.mib.2011.10.012.
19. Kim HK, Missiakas D, Schneewind O. 2014. Mouse models for infectious diseases caused by Staphylococcus aureus. J Immunol Methods 410:88-99. http://dx.doi.org/10.1016/j.jim.2014.04.007.
20. Brown M, Kowalski R, Zorman J, Wang X-M, Towne V, Zhao Q, Secore S, Finnefrock AC, Ebert T, Pancari G, Isett K, Zhang Y, Anderson AS, Montgomery D, Cope L, McNeely T. 2009. Selection and characterization of murine monoclonal antibodies to Staphylococcus aureus ironregulated surface determinant B with functional activity in vitro and in vivo. Clin Vaccine Immunol 16:1095-1104. http://dx.doi.org/10.1128/CVI.00085-09.
21. Ebert T, Smith S, Pancari G, Clark D, Hampton R, Secore S, Towne V, Fan H, Wang X-M, Wu X, Ernst R, Harvey BR, Finnefrock AC, Wang F, Tan C, Durr E, Cope L, Anderson A, An Z, McNeely T. 2010. A fully human monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB) with functional activity in vitro and in vivo. HumAntibodies 19:113-128. http://dx.doi.org/10.3233/HAB-2010-0235.
22. Fritz SA, Tiemann KM, Hogan PG, Epplin EK, Rodriguez M, Al-Zubeidi DN, Bubeck Wardenburg J, Hunstad DA. 2013. A serologic correlate of protective immunity against community-onset Staphylococcus aureus infection. Clin Infect Dis 56:1554-1561. http://dx.doi.org/10.1093/cid/cit123.
23. Pancari G, Fan H, Smith S, Joshi A, Haimbach R, Clark D, Li Y, Hua J, McKelvey T, Ou Y, Drummond J, Cope L, Montgomery D, McNeely T. 2012. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron-regulated surface determinant B (IsdB). Front Cell Infect Microbiol 2:36. http://dx .doi.org/10.3389/fcimb.2012.00036.
24. Holtfreter S, Kolata J, Broker BM. 2010. Towards the immune proteome of Staphylococcus aureus: the anti-S. aureus antibody response. Int J Med Microbiol 300:176-192. http://dx.doi.org/10.1016/j.ijmm.2009.10.002.
25. Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, Hyde C, Chapel H, the UKPIN. 2007. Recognition, clinical diagnosis, and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 149:410-423.
26. Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, Kustos T, Henics T, Meinke A, Nagy E. 2005. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 12:387-398.
27. Nauseef WM. 2007. How human neutrophils kill and degrade microbes:an integrated view. Immunol Rev 219:88-102. http://dx.doi.org/10.1111/j.1600-065X.2007.00550.x.
28. Rigby K, DeLeo F. 2012. Neutrophils in innate host defense against Staphylococcus aureus infections. Semin Immunopathol 34:237-259. http://dx.doi.org/10.1007/s00281-011-0295-3.
29. Verdrengh M, Tarkowski A. 1997. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun 65:2517-2521.
30. Mölne L, Verdrengh M, Tarkowski A. 2000. Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect Immun 68:6162-6167. http://dx.doi.org/10.1128/IAI.68.11.6162-6167.2000.
31. Boxer LA. 2012. How to approach neutropenia. ASH Education Program Book 2012:174-182.
32. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. 2014. The function of Fc g receptors in dendritic cells and macrophages. Nat Rev Immunol 14:94-108. http://dx.doi.org/10.1038/nri3582.
33. Selvaraj P, Fifadara N, Nagarajan S, Cimino A, Wang G. 2004. Functional regulation of human neutrophil Fcγ receptors. Immunol Res 29:219-229. http://dx.doi.org/10.1385/IR:29:1-3:219.
34. Deleo FR. 2004. Modulation of phagocyte apoptosis by bacterial pathogen. Apoptosis 9:399-413. http://dx.doi.org/10.1023/B:APPT.0000031448.64969.fa.
35. Kennedy AD, Wardenburg JB, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alphahemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050-1058. http://dx.doi.org/10.1086/656043.
36. Kamei A, Wu W, Traficante DC, Koh AY, Van Rooijen N, Pier GB, Priebe GP. 2013. Collaboration between macrophages and vaccineinduced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis 207:39-49. http://dx.doi.org/10.1093/infdis/jis657.
37. Scarff JM, Goldberg JB. 2008. Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice. Clin Vaccine Immunol 15:367-375. http://dx.doi.org/10.1128/CVI.00419-07.